โ Home
โน๏ธ Info
๐งพ At a Glance ๐ Core Facts ๐๏ธ Products/Services โญ Ratings ๐งโ๐ผ Executives ๐ฌ My Comments๐ก Analytics
๐ Insights ๐ข Company Q&A (663) ๐ ๏ธ Industry Q&A (164) ๐ Competitors ๐ Price Low ๐ Price Swings โก SWOT ๐๏ธ PEST ๐ Porter's Five Forces โจ Score Positive โ ๏ธ Risk Assessment ๐งฉ Segmentation ๐ ถ Google Links๐ Ratios
๐ฐ Margins ๐ Financial Ratios ๐ฑ Growth ๐ Enterprise Value ๐ Key Metrics ๐ต Dividends๐ง Tools
โ Due Diligence๐ข Press Releases
| Date | Press release |
|---|---|
| 2026-06-11 10:00:00 | Investor Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Adc Therapeutics Sa - Adct New york, june 11, 2026 /prnewswire/ --ย pomerantz llp is investigating claims on behalf of investors of adc therapeutics sa (โadcโ or the โcompanyโ) (nyse: adct). such investors are advised to contact danielleย peyton at newaction@pomlaw.comย or 646-581-9980, ext. |
| 2026-06-09 13:20:00 | Investor Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Adc Therapeutics Sa - Adct New york, june 09, 2026 (globe newswire) -- pomerantz llp is investigating claims on behalf of investors of adc therapeutics sa (โadcโ or the โcompanyโ) (nyse: adct). such investors are advised to contact danielle peyton atย newaction@pomlaw.com ย or 646-581-9980, ext.ย 7980. |
| 2026-06-08 16:05:00 | Agree Realty Declares Monthly Common And Preferred Dividends Royal oak, mich.--(business wire)--agree realty corporation (nyse: adc) (the โcompanyโ) today announced that its board of directors has authorized, and the company has declared, a monthly cash dividend of $0.267 per common share. the monthly dividend reflects an annualized dividend amount of $3.204 per common share, representing a 4.3% increase over the annualized dividend amount of $3.072 per common share from the second quarter of 2025. the dividend is payable july 15, 2026 to stockholders of. |
| 2026-06-04 09:30:00 | Akari Therapeutics Releases Ceo Corner Reflecting On Evolving Adc Landscape And Akariโs Differentiated Ph1 Payload Platform Following Asco 2026 Discussion highlights growing importance on novel adc payloads, and akariโs asco data in kras-driven cancers and future potential |
| 2026-06-03 16:05:00 | Adc Therapeutics Announces Results From Lotis-5 Phase 3 Confirmatory Clinical Trial Of Zynlontaยฎ In Combination With Rituximab In Relapsed Or Refractory Diffuse Large B-cell Lymphoma Company to host conference call today at 4:30 p.m. edt lausanne, switzerland, june 3, 2026 /prnewswire/ -- adc therapeutics sa (nyse: adct) today announced topline data from its phase 3 lotis-5 confirmatory trial evaluating zynlontaยฎ (loncastuximab tesirine-lpyl) in combination with rituximab in patients with relapsed or refractory diffuse large b-cell lymphoma (r/r dlbcl). |
| 2026-05-21 17:05:00 |
|
| 2026-05-19 03:15:00 |
|
| 2026-05-12 16:05:00 |
|
| 2026-05-12 08:33:00 |
|
| 2026-05-06 22:25:00 |
|
| 2026-05-06 08:00:00 |
|
| 2026-05-04 07:30:00 |
|
| 2026-05-01 04:05:00 |
|
| 2026-04-29 16:15:00 |
|
| 2026-04-27 07:30:00 |
|
๐ฐ Browse additional press releases for Agree Realty Corp!
Sign up for free or log in๐ Free download! "The Checklist Value Investor โ A Smarter Way to Pick Stocks"